Resources & Evidence Contact us

582 Results:

Sort By:

The story of Lillie, as told by her mom, Abbie

Type: Parent Stories

Topic(s): 22-27 weeks (extremely premature)

Preterm infants fed Prolacta’s 100% human milk-based fortifiers achieved catch-up growth by age 2 with appropriate neurodevelopmental outcomes, study says

Type: Press Releases

Topic(s): Growth Long-Term outcomes

Head-to-head subgroup analysis of human milk–based fortifiers finds significant improvements in health and brain growth measure for preemies fed mother’s milk plus Prolacta’s fortifiers

Type: Press Releases

Topic(s): Growth Neurodevelopmental Outcomes Total Parenteral Nutrition (TPN) Use

The story of Kallie, as told by her mom, Ebonie

Type: Parent Stories

Topic(s): 22-27 weeks (extremely premature)

Donor Sarah

Type: Donor Stories

Topic(s): Tiny Treasures

The story of Evelyne, as told by her mom, Tiffany

Type: Parent Stories

Topic(s): 28-32 weeks (very premature)

Prolacta Bioscience reassures hospitals of the safety of its human milk-based nutritional products during the coronavirus pandemic

Type: Press Releases

Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Pasteurization Quality & Safety

Providing safe nutritional products during the Coronavirus outbreak

Type: Blog

Topic(s): Quality & Safety

Donor Ashlee

Type: Donor Stories

Topic(s): Tiny Treasures

Not finding the reference you’re looking for?

Use our main search field or email us at info@prolacta.com